SEC Filing Summary: Galena Biopharma, Inc.
Business Context and Reporting Period
This Form 8-K was filed by Galena Biopharma, Inc. on March 13, 2017, reporting an event that occurred on March 7, 2017. The registrant is a Delaware corporation headquartered in San Ramon, California.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes.
Material Changes
The primary material change reported is the appointment of Stephen F. Ghiglieri as the Company's principal accounting officer, effective immediately on March 7, 2017. Mr. Ghiglieri currently serves as the Interim Chief Executive Officer and Chief Financial Officer.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Stephen F. Ghiglieri has been appointed as the principal accounting officer.
- The appointment is effective as of March 7, 2017.
- Mr. Ghiglieri holds concurrent roles as Interim CEO and CFO.
- No financial performance data is included in this specific filing.